603 related articles for article (PubMed ID: 27198953)
1. Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data.
Snyder E; Ma J; Svetnik V; Connor KM; Lines C; Michelson D; Herring WJ
Sleep Med; 2016 Mar; 19():93-100. PubMed ID: 27198953
[TBL] [Abstract][Full Text] [Related]
2. Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects.
Ma J; Svetnik V; Snyder E; Lines C; Roth T; Herring WJ
Sleep; 2014 Oct; 37(10):1609-19. PubMed ID: 25197807
[TBL] [Abstract][Full Text] [Related]
3. Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials.
Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
J Clin Sleep Med; 2016 Sep; 12(9):1215-25. PubMed ID: 27397664
[TBL] [Abstract][Full Text] [Related]
4. Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials.
Herring WJ; Connor KM; Ivgy-May N; Snyder E; Liu K; Snavely DB; Krystal AD; Walsh JK; Benca RM; Rosenberg R; Sangal RB; Budd K; Hutzelmann J; Leibensperger H; Froman S; Lines C; Roth T; Michelson D
Biol Psychiatry; 2016 Jan; 79(2):136-48. PubMed ID: 25526970
[TBL] [Abstract][Full Text] [Related]
5. Insight Into Reduction of Wakefulness by Suvorexant in Patients With Insomnia: Analysis of Wake Bouts.
Svetnik V; Snyder ES; Tao P; Scammell TE; Roth T; Lines C; Herring WJ
Sleep; 2018 Jan; 41(1):. PubMed ID: 29112763
[TBL] [Abstract][Full Text] [Related]
6. Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data.
Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
Psychopharmacology (Berl); 2017 Jun; 234(11):1703-1711. PubMed ID: 28265715
[TBL] [Abstract][Full Text] [Related]
7. Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials.
Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
Am J Geriatr Psychiatry; 2017 Jul; 25(7):791-802. PubMed ID: 28427826
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic effects of suvorexant and zolpidem on EEG during sleep in healthy subjects.
Struyk A; Gargano C; Drexel M; Stoch SA; Svetnik V; Ma J; Mayleben D
Eur Neuropsychopharmacol; 2016 Oct; 26(10):1649-56. PubMed ID: 27554636
[TBL] [Abstract][Full Text] [Related]
9. Can the Orexin Antagonist Suvorexant Preserve the Ability to Awaken to Auditory Stimuli While Improving Sleep?
Drake CL; Kalmbach DA; Cheng P; Roth T; Tran KM; Cuamatzi-Castelan A; Atkinson R; Singh M; Tonnu CV; Fellman-Couture C
J Clin Sleep Med; 2019 Sep; 15(9):1285-1291. PubMed ID: 31538599
[TBL] [Abstract][Full Text] [Related]
10. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.
Herring WJ; Snyder E; Budd K; Hutzelmann J; Snavely D; Liu K; Lines C; Roth T; Michelson D
Neurology; 2012 Dec; 79(23):2265-74. PubMed ID: 23197752
[TBL] [Abstract][Full Text] [Related]
11. Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.
Owen RT
Drugs Today (Barc); 2016 Jan; 52(1):29-40. PubMed ID: 26937493
[TBL] [Abstract][Full Text] [Related]
12. Effects of suvorexant on the Insomnia Severity Index in patients with insomnia: analysis of pooled phase 3 data.
Herring WJ; Connor KM; Snyder E; Snavely DB; Morin CM; Lines C; Michelson D
Sleep Med; 2019 Apr; 56():219-223. PubMed ID: 30522875
[TBL] [Abstract][Full Text] [Related]
13. Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2014 Dec; 68(12):1429-41. PubMed ID: 25231363
[TBL] [Abstract][Full Text] [Related]
14. Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease.
Sun H; Palcza J; Rosenberg R; Kryger M; Siringhaus T; Rowe J; Lines C; Wagner JA; Troyer MD
Respir Med; 2015 Mar; 109(3):416-26. PubMed ID: 25661282
[TBL] [Abstract][Full Text] [Related]
15. Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.
Patel KV; Aspesi AV; Evoy KE
Ann Pharmacother; 2015 Apr; 49(4):477-83. PubMed ID: 25667197
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial.
Michelson D; Snyder E; Paradis E; Chengan-Liu M; Snavely DB; Hutzelmann J; Walsh JK; Krystal AD; Benca RM; Cohn M; Lines C; Roth T; Herring WJ
Lancet Neurol; 2014 May; 13(5):461-71. PubMed ID: 24680372
[TBL] [Abstract][Full Text] [Related]
17. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications.
Herring WJ; Roth T; Krystal AD; Michelson D
J Sleep Res; 2019 Apr; 28(2):e12782. PubMed ID: 30338596
[TBL] [Abstract][Full Text] [Related]
18. Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects.
Uemura N; McCrea J; Sun H; Donikyan M; Zammit G; Liu R; Louridas B; Marsilio S; Lines C; Troyer MD; Wagner J
J Clin Pharmacol; 2015 Oct; 55(10):1093-100. PubMed ID: 25903940
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, randomized, placebo-controlled trial of suvorexant for the treatment of vasomotor symptom-associated insomnia disorder in midlife women.
Rahman SA; Nathan MD; Wiley A; Crawford S; Cohn AY; Harder JA; Grant LK; Erickson A; Srivastava A; McCormick K; Bertisch SM; Winkelman JW; Joffe H
Sleep; 2022 Mar; 45(3):. PubMed ID: 35022783
[TBL] [Abstract][Full Text] [Related]
20. Sleep and pain in humans with fibromyalgia and comorbid insomnia: double-blind, crossover study of suvorexant 20 mg versus placebo.
Roehrs T; Withrow D; Koshorek G; Verkler J; Bazan L; Roth T
J Clin Sleep Med; 2020 Mar; 16(3):415-421. PubMed ID: 31992394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
